AbbVie stock gains ahead of earnings; ABBV investors brace for guidance and a $1.3 billion expense
AbbVie shares rose 1.2% to $225.70 Monday ahead of its Feb. 4 earnings release, which will include a $1.3 billion charge tied to acquired R&D and milestone expenses. The company expects fourth-quarter adjusted earnings between $2.61 and $2.65 per share. A webcast is scheduled for 8 a.m. Central.